FIL Ltd Buys 5,232 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FIL Ltd lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 106,041 shares of the biopharmaceutical company's stock after acquiring an additional 5,232 shares during the period. FIL Ltd owned 0.10% of Regeneron Pharmaceuticals worth $75,536,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $36,000. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Finally, Private Wealth Management Group LLC increased its stake in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $10.09 on Tuesday, reaching $560.97. 265,786 shares of the company's stock were exchanged, compared to its average volume of 706,929. The firm has a market capitalization of $61.33 billion, a price-to-earnings ratio of 14.65, a PEG ratio of 2.34 and a beta of 0.44. The business's 50-day moving average is $657.03 and its two-hundred day moving average is $749.93. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $11.86 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $964.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.